Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2010
12/29/2010WO2009132048A8 Treating eosinophilic esophagitis
12/29/2010EP2267454A2 Diagnosis and prevention of cancer cell invasion
12/29/2010EP2267445A1 Methods of detecting small intestinal bacterial overgrowth (SIBO) in a human subject
12/29/2010EP2267431A2 Gas sensor
12/29/2010EP2267154A1 Oligoadenylate synthetase
12/29/2010EP2267036A1 Hypo- and Hyper-Acetylated Meningococcal Capsular Saccharides
12/29/2010EP2267029A2 Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
12/29/2010EP2266994A1 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
12/29/2010EP2266990A1 3-PHENYLPYRAZOLOÝ5,1-b¨THIAZOLE COMPOUND
12/29/2010EP2266989A2 Heterocyclic derivatives
12/29/2010EP2266988A1 [3.2.0] Heterocyclic compounds and methods of using the same
12/29/2010EP2266987A1 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
12/29/2010EP2266986A1 Cytotoxins, Prodrugs, Linkers and Stabilizers useful therefor
12/29/2010EP2266985A1 Tricyclic Pyrimidine Derivatives as Wnt antagonists
12/29/2010EP2266984A1 Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
12/29/2010EP2266983A1 Nitrogenated 5-membered heterocyclic compound
12/29/2010EP2266981A2 Benzothiazole compounds useful as kinase inhibitors
12/29/2010EP2266980A1 Polymorphic form of aprepitant intermediate
12/29/2010EP2266979A1 2-morpholino-4-pyrimidone compounds
12/29/2010EP2266978A1 Novel physiologically active substances
12/29/2010EP2266977A1 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors
12/29/2010EP2266976A1 Fused ring thrombin receptor antagonists
12/29/2010EP2266975A1 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds
12/29/2010EP2266974A1 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts
12/29/2010EP2266973A1 Pyrazinylpyrazole
12/29/2010EP2266972A1 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
12/29/2010EP2266971A2 Hiv protease inhibiting compounds
12/29/2010EP2266970A1 Substituted aromatic heterocyclic compounds as fungicides
12/29/2010EP2266969A2 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
12/29/2010EP2266968A2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
12/29/2010EP2266965A1 Methods for Isolating Crystalline Form I of 5-Azacytidine
12/29/2010EP2266964A1 Acid-labile trigger units
12/29/2010EP2266962A1 The compounds as the estrogen related receptors modulators and the uses thereof
12/29/2010EP2266960A2 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants
12/29/2010EP2266959A1 8-carboxamido-substituted-2, 6-methano-3-benzazocines and 3-carboxamido-substituted morphanes as opioid receptor binding agents
12/29/2010EP2266958A1 Antiviral agent
12/29/2010EP2266956A2 Pleuromutilin derivatives useful as antibacterials
12/29/2010EP2266955A1 Mutilin derivatives and their use as pharmaceutical
12/29/2010EP2266954A1 Novel bifunctional chelating compounds containing hydroxamic acid residues
12/29/2010EP2266953A1 Novel bifunctional chelating compounds containing hydroxamic acid residues
12/29/2010EP2266951A1 Organic compounds
12/29/2010EP2266950A1 Ceramide dimers and their use as medicine or cosmetic preparation
12/29/2010EP2266948A1 Salts of tramadol and diflunisal and their crystal form in the treatment of pain
12/29/2010EP2266947A1 Ester derivatives as competitive inhibitors of type II dehydroquinase enzyme
12/29/2010EP2266946A2 Compound For The Treatment Of Metabolic Disorders
12/29/2010EP2266719A2 Disposal system for transdermal dosage form
12/29/2010EP2266718A2 Disposal system for transdermal dosage form
12/29/2010EP2266665A1 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
12/29/2010EP2266656A2 Devices for delivering a biologically active agent to the ocular sphere of a subject
12/29/2010EP2266628A2 Method of determining the susceptibility to bone meatastases by EPhA2 expression
12/29/2010EP2266626A1 Composition for external application comprising transcription factor decoy as active ingredient
12/29/2010EP2266621A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics
12/29/2010EP2266620A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics
12/29/2010EP2266619A1 Pharmaceutical composition based on hepatoprotector and prebiotic, the production and use thereof
12/29/2010EP2266607A2 Immunoconjugates for treating cancer
12/29/2010EP2266600A2 Therapeutic composition with a botulinum neurotoxin
12/29/2010EP2266599A2 Therapeutic composition with a botulinum neurotoxin
12/29/2010EP2266598A1 Method of increasing bone toughness and stiffness and reducing fractures
12/29/2010EP2266590A2 Active agent delivery sytems and methods for protecting and administering active agents
12/29/2010EP2266585A2 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
12/29/2010EP2266584A2 Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions
12/29/2010EP2266583A1 Gene expression inhibitor selective for matrix metalloproteinase-9 gene
12/29/2010EP2266582A1 Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics
12/29/2010EP2266581A1 Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy
12/29/2010EP2266580A1 Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
12/29/2010EP2266579A1 Pharmaceutical composition comprising elvucitavine
12/29/2010EP2266578A1 Pharmaceutical composition for preventing and treating bone resorption of different etiology
12/29/2010EP2266577A1 Multi-substitued selective androgen receptor modulators and methods of use therof
12/29/2010EP2266576A1 Treatment of diabetes with thiazolidinedione and sulphonylurea
12/29/2010EP2266575A2 Use of Norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels
12/29/2010EP2266574A1 Therapeutic use on-demand of formoterol and budesonide
12/29/2010EP2266573A1 Fulvestrant formulation
12/29/2010EP2266572A1 Use of pyrimidylaminobenzamide derivatives for the treatment of hypereosinophilic syndrome
12/29/2010EP2266571A1 Pharmaceutical combinations for treating lower urinary tract disfunctions
12/29/2010EP2266570A1 Use of binding partners for 5-HT5 receptors for treating neurodegenerative and neuropsychiatric disorders
12/29/2010EP2266569A2 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
12/29/2010EP2266568A1 Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
12/29/2010EP2266567A1 Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
12/29/2010EP2266566A2 Nicotinamide derivatives and their use as therapeutic agents
12/29/2010EP2266565A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
12/29/2010EP2266564A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
12/29/2010EP2266563A1 Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
12/29/2010EP2266562A1 Use of derivatives of indoles for the treatment of cancer
12/29/2010EP2266561A2 IKK Inhibitors for the Treatment of Endometriosis
12/29/2010EP2266560A1 Benzothiophenes, formulations containing same, and methods
12/29/2010EP2266559A1 Therapeutic agent for ophthalmic disease
12/29/2010EP2266558A2 Treatment of neuropathic pain with N-methyl-D-aspartate (NMDA) receptor antagonists
12/29/2010EP2266557A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
12/29/2010EP2266556A1 Water-based adhesive skin patch comprising ketoprofen lysine salt
12/29/2010EP2266555A2 Compounds with antiparasitic activity and medicines containing same
12/29/2010EP2266554A1 Method of treating sleep disorders using eplivanserin
12/29/2010EP2266553A1 Butenafine hydrochloride-containing aqueous patch
12/29/2010EP2266552A2 Methods of inducing terminal differentiation
12/29/2010EP2266551A1 Compositions and kits comprising a defined boron compound and methods of their preparation
12/29/2010EP2266550A1 Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
12/29/2010EP2266549A2 Method of making particles for use in a pharmaceutical composition
12/29/2010EP2266548A2 Dry powder for inhalation
12/29/2010EP2266547A1 Composition for the transdermal delivery of fentanyl
12/29/2010EP2266545A1 Microencapsulation of essential oils with an enteric matrix
12/29/2010EP2266542A2 Controlled release nanoparticulate compositions
1 ... 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 ... 7860